McKesson price target raised to $575 from $559 at UBS

UBS raised the firm’s price target on McKesson to $575 from $559 and keeps a Buy rating on the shares. The firm is “a little more concerned” for Q4 where the midpoint of Pharma revenue and EBIT growth guidance implies McKesson should see an EBIT margin of 1.27%, but UBS still believes McKesson should be able to see annual margin expansion over the long run, the analyst tells investors in a research note.